公开(公告)号：US20230374006A1

公开(公告)日：2023-11-23

申请号：US18229588

申请日：2023-08-02

申请人： APRINOIA THERAPEUTICS LIMITED

发明人： Ming-Kuei JANG ,  Paul TEMPEST

IPC分类号： C07D471/04 ,  A61K49/00 ,  A61K51/04 ,  C07D401/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14 ,  C07D495/04 ,  G01N33/68

CPC分类号： C07D471/04 ,  A61K49/0021 ,  A61K51/0455 ,  C07D401/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14 ,  C07D495/04 ,  G01N33/6896 ,  G01N2800/2821

摘要： Described herein are compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, isotopically labeled derivatives and radiolabeled derivative thereof, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for detecting and imaging Tau aggregates in the brain for detection of Alzheimer's disease (AD) in a subject.

公开(公告)号：US20220267316A1

公开(公告)日：2022-08-25

申请号：US17687570

申请日：2022-03-04

申请人： Aprinoia Therapeutics Limited

发明人： Paul TEMPEST ,  Ming-Kuei JANG ,  Yih-Shyan LIN

IPC分类号： C07D417/14 ,  C07D471/04 ,  C07D413/14

摘要： Disclosed herein are novel compounds for degrading Tau protein aggregates, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof. Also disclosed herein are uses of the compounds, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof in manufacture a medicament for treating a tauopathy, as well as method for aiding in the treatment of a tauopathy or treating a tauopathy in a subject.

公开(公告)号：US20220354835A1

公开(公告)日：2022-11-10

申请号：US17320882

申请日：2021-05-14

申请人： Aprinoia Therapeutics Limited

发明人： Ming-Kuei JANG ,  Paul TEMPEST ,  Yih-Shyan LIN

IPC分类号： A61K31/4439 ,  A61K47/54 ,  A61K31/444

摘要： Disclosed herein are novel compounds for degrading Tau protein aggregates, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof. Also disclosed herein are uses of the compounds, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof in the manufacture of a medicament for treating a tauopathy, as well as method for aiding in the treatment of a tauopathy or treating a tauopathy in a subject.

公开(公告)号：US20230346955A1

公开(公告)日：2023-11-02

申请号：US18140863

申请日：2023-04-28

申请人： Aprinoia Therapeutics Limited

发明人： Paul TEMPEST ,  Ming-Kuei JANG ,  Yih-Shyan LIN

IPC分类号： A61K47/55 ,  A61P25/28 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/506 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  A61K47/54 ,  A61K31/444

CPC分类号： A61K47/55 ,  A61P25/28 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/506 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  A61K47/545 ,  A61K47/54 ,  A61K31/444

摘要： Disclosed herein are novel compounds for degrading Tau protein aggregates, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof. Also disclosed herein are uses of the compounds, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof in manufacture a medicament for treating a tauopathy, as well as method for aiding in the treatment of a tauopathy or treating a tauopathy in a subject.

公开(公告)号：US20220280650A1

公开(公告)日：2022-09-08

申请号：US17687550

申请日：2022-03-04

申请人： APRINOIA THERAPEUTICS LIMITED

发明人： Ming-Kuei JANG ,  Paul TEMPEST ,  Yih-Shyan LIN

IPC分类号： A61K47/55 ,  A61P25/28 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/506

摘要： The present disclosure provides compounds, compositions and methods useful for the treatment of neurodegenerative diseases, in particular synucleinopathies.